We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension (CO in PAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01523548
Recruitment Status : Withdrawn (Lack of funding and subject acuity)
First Posted : February 1, 2012
Last Update Posted : June 9, 2017
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Roberto Machado, M.D., University of Illinois at Chicago

January 27, 2012
February 1, 2012
June 9, 2017
July 2012
December 2018   (Final data collection date for primary outcome measure)
Evidence of a 20% decrease in pulmonary vascular resistance post-therapy when compared to pre-therapy value [ Time Frame: At baseline and after 16 weeks ]
Same as current
Complete list of historical versions of study NCT01523548 on ClinicalTrials.gov Archive Site
  • Effect of 16-weeks CO inhalation on other pulmonary and systemic hemodynamic parameters [ Time Frame: 16 weeks ]
  • Effect of 16-weeks CO inhalation on functional capacity assessed by six-minute walk test [ Time Frame: 16 weeks ]
  • Effect of 16-weeks CO inhalation on Brain Natriuretic Peptide levels [ Time Frame: 16 weeks ]
  • Effect of 16-weeks CO inhalation on right ventricular echocardiographic parameters [ Time Frame: 16 weeks ]
  • Effect of 16-weeks CO inhalation on acute pulmonary vasoreactivity [ Time Frame: 16 weeks ]
Same as current
Not Provided
Not Provided
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

The purpose of this study is to examine the potential of carbon monoxide (CO) to decrease elevated blood pressure in the pulmonary artery. This symptom is seen in patients with pulmonary arterial hypertension, a rare disease that causes fatigue, dizziness, and shortness of breath because the blood vessels that supply the lungs narrow, forcing the heart to work harder to push blood through. Previous studies in the laboratory have shown that carbon monoxide has promise in treating these symptoms.

Subjects in this study are being asked to undergo a new type of treatment to improve pulmonary arterial hypertension by breathing CO gas. CO is a colorless, tasteless, odorless gas usually found in car exhaust or cigarette smoke. It is administered with a continuous flow of air. Subjects will undergo a screening process during which it will be determined if they are eligible for the study. After the screening process, if subjects meet eligibility criteria for the study, they will begin carbon monoxide treatment through a cushioned mask that is placed over the nose and mouth. This treatment will last for sixteen weeks.

Pulmonary arterial hypertension (PAH) remains an uncommon debilitating and fatal disease, and is clinically marked by a progressive increase in pulmonary vascular resistance leading to right heart failure and ultimately death. Currently the treatment options available for those suffering from PAH target cellular dysfunction that leads to constriction of the vasculature. Although there is some evidence that available therapies have secondary effects on vascular remodeling there are currently no therapies that target abnormal cell proliferation in PAH.

Carbon monoxide (CO) is a gaseous molecule with known toxicity and lethality to living organisms when exposed to high concentrations for sustained periods. However, CO has shown promise in preclinical models of pulmonary hypertension. Recent studies have shown that mammalian cells have the ability to generate endogenous CO primarily through the catalysis of heme by the heme oxygenase enzymatic system and there is ample evidence demonstrating that CO behaves as a signaling molecule in cellular and biological processes. Furthermore, CO has been demonstrated to exert key physiological and protective functions in various models of tissue inflammation and injury.

This study will evaluate the safety and potential efficacy of inhaled CO in subjects with severe PAH. Over forty subjects with severe PAH despite best available therapy will be screened from the UIC pulmonary vascular disease clinic, of which twenty subjects will be recruited for participation in the trial. The trial will consist of an initial screening period to determine subjects' eligibility for the study. This will be based on a previous echocardiogram, a six minute walk test and right heart catheterization done as part of standard care for subjects with pulmonary arterial hypertension. Following the initial screening, the trial will last sixteen weeks, during which subjects will receive inhaled carbon monoxide up to three times weekly at the University of Illinois at Chicago.

Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypertension, Pulmonary
Drug: Carbon Monoxide
150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
Experimental: Carbon Monoxide
Inhaled Carbon Monoxide therapy administered over 16 weeks
Intervention: Drug: Carbon Monoxide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2018
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • male and female ≥ 18 years old , with Pulmonary Arterial Hypertension
  • Right heart catheterization diagnosis of PAH:

    • Mean Pulmonary Artery Pressure (mPAP)> 25 mmHg at rest
    • Pulmonary Capillary Occlusion Pressure (PCOP) or Left Ventricular End Diastolic Pressure (LVEDP) < 15 mmHg
    • Pulmonary Vascular Resistance (PVR) > 3 mmHg/L/min
  • Must be Class 1.1, 1.2, or 1.3 PAH (see Appendix A)
  • Echocardiographic evidence of Right Ventricular Dysfunction
  • On standard and stable PAH therapy (no dose changes in the 4 weeks prior to starting the study medication) including:

    • A Prostacyclin (IV epoprostenol, IV or subcutaneous remodulin, inhaled iloprost or remodulin) unless willing or unable to tolerate therapy AND
    • Phosphodiesterase type 5 inhibitor OR
    • Endothelin Receptor Antagonist OR
    • Any combination of a-c
  • NYHA class III or IV despite 3 months of stable therapy as outlined above
  • 6 minute walk distance ≤ 380m
  • Negative serum pregnancy test
  • Female of childbearing age either surgically sterilized or using acceptable method of contraception. Acceptable methods of contraception include oral contraceptives, IUD, or other barrier methods of contraception.

Exclusion Criteria:

  • History of malignancy in 2 years prior to enrollment
  • Baseline cytopenia's:

    • White blood cell count ≤ 3,000 i. Absolute Neutrophil Count (ANC) less than 1500 cells/mm3
    • Hemoglobin ≤ 7
    • Platelet ≤ 100,000
  • Baseline Liver Disease:

    • ALT/AST, ALk phos > 2.5x ULN, INR > 1.5
    • Bilirubin > 1.5 x ULN
  • Coronary artery disease
  • Any cause of pulmonary hypertension other than class 1.1, 1.2, or 1.3 PAH.
  • Baseline Renal Disease: Cr ≥ 2
  • Active Smoker
  • Hypoxemia with SaO2 < 95% on oxygen 2 L/min
  • Baseline COHb > 2%
  • Pregnancy or lactation
  • Inability to attend scheduled clinic visits
  • Previous lung transplant
  • Naive to available standard PAH therapy
  • Pulmonary Capillary Occlusion Pressure (PCOP) or LEft Ventricular End Diastolic Pressure (LVEDP)< 15 mmHg
  • Concomitant enrollment in another investigational treatment protocol for PAH or taking any off label drug therapy for PAH
  • Recent enrollment in or plans to enroll in Pulmonary Rehabilitation during the study period
  • Any condition that in the opinion of the investigator would prevent completion of study procedures
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
K23HL098454 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Roberto Machado, M.D., University of Illinois at Chicago
University of Illinois at Chicago
  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Roberto F Machado, MD University of Illinois at Chicago
University of Illinois at Chicago
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP